AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2-positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour-agnostic indication. This broadens its potential to help more patients with advanced HER2-positive cancers.